ASIP: A Protein Regulating Tyrosine Kinase Activity (G434)

Target Name: ASIP

NCBI ID: G434

ASIP

ASIP: A Protein Regulating Tyrosine Kinase Activity

ASIP (ASIP variant X1) is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the regulation of the cytoskeleton. It is a member of the ASIP family, which includes several similar proteins that are involved in the regulation of cell signaling pathways. One of the key functions of ASIP is to regulate the activity of tyrosine kinases, which are enzymes that play a central role in the regulation of cellular processes such as cell growth, differentiation, and survival.

ASIP has been shown to play a key role in the regulation of the activity of several tyrosine kinases, including Src, Fyn, and Kaes. It has been shown that ASIP can inhibit the activity of these tyrosine kinases by interacting with their extracellular domains and preventing them from interacting with DNA. This interaction between ASIP and tyrosine kinases is critical for the regulation of cellular processes, as ASIP plays a key role in the regulation of tyrosine kinase activity during periods of cell growth and division.

In addition to its role in regulating tyrosine kinase activity, ASIP has also been shown to play a role in the regulation of several other cellular processes. For example, it has been shown to be involved in the regulation of mitochondrial function, as well as the regulation of cellular responses to environmental stimuli.

ASIP is also of interest as a potential drug target, as several compounds that inhibit ASIP activity have been shown to have therapeutic effects in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, a compound called U012 has been shown to inhibit the activity of ASIP and to have therapeutic effects in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

ASIP is also of interest as a potential biomarker, as its expression has been shown to be regulated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes ASIP a promising candidate for use as a biomarker for these diseases, as it can be used as a diagnostic tool and as a target for drug development.

Overall, ASIP is a protein that is involved in the regulation of several cellular processes, including the regulation of tyrosine kinase activity and the regulation of mitochondrial function. Its role in these processes makes ASIP a potential drug target and a promising candidate for use as a biomarker for a variety of diseases. Further research is needed to fully understand the mechanisms of ASIP's function and its potential as a drug and biomarker.

Protein Name: Agouti Signaling Protein

Functions: Involved in the regulation of melanogenesis. The binding of ASP to MC1R precludes alpha-MSH initiated signaling and thus blocks production of cAMP, leading to a down-regulation of eumelanogenesis (brown/black pigment) and thus increasing synthesis of pheomelanin (yellow/red pigment). In higher primates, agouti may affect the quality of hair pigmentation rather than its pattern of deposition. Could well play a role in neuroendocrine aspects of melanocortin action. May have some functional role in regulating the lipid metabolism with adipocytes

The "ASIP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASIP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets